Dragana Bugarski-Kirola Selected Research

(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanone

1/2017	Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
12/2016	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
8/2014	Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dragana Bugarski-Kirola Research Topics

Disease

6	Schizophrenia (Dementia Praecox) 01/2022 - 08/2003
1	Toothache (Toothaches) 01/2022
1	Neurobehavioral Manifestations 12/2004

Drug/Important Bio-Agent (IBA)

5	Antipsychotic Agents (Antipsychotics)IBA 01/2017 - 08/2003
3	(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanoneIBA 01/2017 - 08/2014
1	pimavanserinIBA 01/2022
1	Cycloserine (Seromycin)FDA Link 12/2004
1	Haloperidol (Haldol)FDA LinkGeneric 08/2003
1	Olanzapine (Zyprexa)FDA Link 08/2003

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2022
1	Therapeutics 08/2014